STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today’s growth in the pharmaceutical industry. BCC Research’s goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.
This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.
A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.
Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.
R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in various drug delivery systems manufacturers and users. Pharmaceutical biotechnical companies and research institutes will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses drug delivery systems in pharmaceutical and biotechnology markets. BCC Research analyzes each market by its type, region and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of drug delivery systems and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, new developments and market trends.

INFORMATION SOURCES

Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of drug delivery systems in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has over 14 years’ of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are: Reagents for Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

REPORT HIGHLIGHTS

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.
This report provides:
• An overview of the global market for drug delivery systems, including the market as seen by the end users of the different applications.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Discussion of the current state, setbacks, innovations, and the future needs of the market.
• Examination of the different categories of drug delivery, broken down by market shares of the leading manufacturers and/or suppliers, as well as acquisitions, mergers, and alliances by companies and global organizations.
• Analyses of the regulatory environment, and the technology involved, including the latest trends and developments.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
INTENDED AUDIENCE 3
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 3
ABOUT THE AUTHOR 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY
REGION, THROUGH 2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY
REGION, 2011-2018 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 9

NEED FOR THE DOSAGE FORMS 9
TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10
CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY 11
SUSTAINED RELEASE DRUG DELIVERY 11
Oral Sustained Release Drug Delivery 11
Intramuscular (IM) Injections or Microsyringes 12
TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG
DELIVERY 12
PRODRUGS 13
Subtypes of Prodrugs 14
TABLE 3 CLASSIFICATION OF PRODRUGS 14
Need for Prodrugs 15
TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15
IMPLANTS AND INTRAUTERINE DEVICES (IUDS) 16
Copper-based Devices 16
Hormonal-based Devices 16
Mechanism 17
TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17
TARGETED DRUG DELIVERY 18
Delivery Vehicles 18
Liposomes 18
TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19
Micelles and Dendrimers 19
Mechanisms of Drug Delivery 19
Advantages of Dendrimers 20
Biodegradable Particles 20
Artificial DNA Nanostructures 20
Monoclonal Antibodies 21
Applications 21
TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22
POLYMERIC DRUG DELIVERY 22
Applications of Polymers in Drug Delivery 22
TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23
Pegylation 23
TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24
Future Perspectives 24
CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION 24
ORAL DRUG DELIVERY 24
TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25
INJECTABLE OR PARENTERAL DRUG DELIVERY 25
TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25
PULMONARY DRUG DELIVERY 26
TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26
NASAL DRUG DELIVERY 27
TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27
ORAL MUCOSAL DRUG DELIVERY 27
TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG
DELIVERY 28
RECTAL DRUG DELIVERY 28
TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28
OCULAR DRUG DELIVERY 29
TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29
TRANSDERMAL DRUG DELIVERY 29
TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29

CHAPTER 4 REGULATORY ASPECTS 32

NEW PRODUCTS APPROVED IN 2009-2013 32
TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32
FDA RECALLS AND SAFETY ALERTS 35
TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35
TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37

CHAPTER 5 NEW DEVELOPMENTS 40

NEW PARTNERSHIPS, MERGERS AND ACQUISITION 40
TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41
NEW PRODUCTS 42
TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43
PIPELINE PRODUCTS 44
TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44

CHAPTER 6 GLOBAL MARKETS 46

MARKET BY TYPE 46
MARKET OVERVIEW 46
MARKET REVENUE 49
TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH
2018 ($ MILLIONS) 49
FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($
MILLIONS) 49
MARKET SHARE 50
TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 50
FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 51
MARKET BY REGION 51
SUSTAINED RELEASE DRUG DELIVERY SYSTEM 51
Market Overview 52
Market Revenue 53
TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 53
FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 53
Market Share 54
TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,
FOR 2012 (%) 54
FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,
FOR 2012 (%) 54
PRODRUGS 54
Market Overview 55
Market Revenue 55
TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 55
FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 55
Market Share 56
TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 56
FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%) 56
IMPLANTS AND IUDS 57
Market Overview 57
Market Revenue 57
TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018
($ MILLIONS) 58
FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($
MILLIONS) 58
Market Share 58
TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 59
FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 59
TRANSMUCOSAL DELIVERY SYSTEMS 59
Market Overview 60
Market Revenue 62
TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 62
FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 62
Market Share 63
TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012
(%) 63
FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012
(%) 63
TARGETED DRUG DELIVERY 63
Market Overview 64
Market Revenue 65
TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 65
FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 65
Market Share 66
TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 66
FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 66
TRANSDERMAL DRUG DELIVERY SYSTEM 66
Market Overview 67
Market Revenue 67
TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 67
FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 68
Market Share 68
TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,
2012 ($ MILLIONS) 68
FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY
REGION, 2012 (%) 68
POLYMERIC DRUG DELIVERY 69
Market Overview 69
Market Revenue 70
TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 70
FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 70
Market Share 71
TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 71
FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 71
MARKET BY END USERS 71
MARKET OVERVIEW 72
MARKET REVENUE 76
TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY
APPLICATIONS, THROUGH 2018 ($ MILLIONS) 77
FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY
APPLICATIONS, 2011-2018 ($ MILLIONS) 77
MARKET SHARE 78
TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,
2012 (%) 79
FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,
2012 (%) 79

CHAPTER 7 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY 81

TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY
TECHNOLOGY, THROUGH 2018 ($ MILLIONS) 81
FIGURE 19 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY
TECHNOLOGY, 2011-2018 ($ MILLIONS) 81
MARKET BY TYPE 82
SUSTAINED RELEASE 83
Market Overview 83
Market Revenue 84
TABLE 43 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY
TYPE, THROUGH 2018 ($ MILLIONS) 85
FIGURE 20 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
BY TYPE, 2011-2018 ($ MILLIONS) 85
PRODRUGS 85
Market Overview 86
Market Revenue 86
TABLE 44 GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 ($ MILLIONS) 86
TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 87
IMPLANTS AND IUDS 88
Market Overview 89
Market Revenue 89
TABLE 45 GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 ($
MILLIONS) 89
FIGURE 22 GLOBAL REVENUE OF IMPLANTS AND IUDS*, 2011-2018 ($ MILLIONS) 89
TARGETED DRUG DELIVERY 90
Market Overview 90
Liposomes 90
Nanoparticles 91
Monoclonal Antibodies 91
Market Revenue 92
TABLE 46 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH
2018 ($ MILLIONS) 92
FIGURE 23 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, 2011-2018
($ MILLIONS) 93
POLYMERIC DRUG DELIVERY 93
Market Overview 93
Market Revenue 94
TABLE 47 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH
2018 ($ MILLIONS) 94
FIGURE 24 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS,
2011-2018 ($ MILLIONS) 95
MARKET BY REGION 95
MARKET OVERVIEW 95
MARKET REVENUES 97
Oral Sustained Release Delivery 97
TABLE 48 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY
REGION, THROUGH 2018 ($ MILLIONS) 97
FIGURE 25 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY
REGION, 2011-2018 ($ MILLIONS) 97
Injectable Sustained Release Delivery 98
TABLE 49 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY
BY REGION, THROUGH 2018 ($ MILLIONS) 99
FIGURE 26 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG
DELIVERY BY REGION, 2011-2018 ($ MILLIONS) 99
Topical Sustained Release Delivery 99
TABLE 50 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY
REGION, THROUGH 2018 ($ MILLIONS) 100
FIGURE 27 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY
BY REGION, 2011-2018 ($ MILLIONS) 100
Prodrugs 100
TABLE 51 GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 ($
MILLIONS) 100
FIGURE 28 GLOBAL REVENUE OF PRODRUGS BY REGION, 2011-2018 ($ MILLIONS) 101
Implants and IUDs 101
TABLE 52 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018
($ MILLIONS) 102
FIGURE 29 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($
MILLIONS) 102
Targeted Drug Delivery 103
TABLE 53 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 103
FIGURE 30 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 103
TABLE 54 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 104
FIGURE 31 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 104
TABLE 55 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY
REGION, THROUGH 2018 ($ MILLIONS) 105
FIGURE 32 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY
REGION, 2011-2018 ($ MILLIONS) 105
Polymeric Drug Delivery 106
Polymers 106
TABLE 56 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 106
FIGURE 33 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 107
Pegylated Drugs 107
TABLE 57 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 107
FIGURE 34 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 108
INDUSTRY STRUCTURE 108
SUSTAINED RELEASE 108
Market Leaders 108
TABLE 58 MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012 108
Market Share 109
TABLE 59 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG
DELIVERY, 2012 (%) 109
FIGURE 35 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG
DELIVERY, 2012 (%) 109
PRODRUGS 110
Market Leaders 110
TABLE 60 MAJOR MANUFACTURERS OF PRODRUGS, 2012 110
Market Share 111
TABLE 61 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%) 111
FIGURE 36 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%) 111
IMPLANTS AND IUDS 112
Market Leaders 112
TABLE 62 MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012 112
Market Share 112
TABLE 63 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012
(%) 112
FIGURE 37 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS,
2012 (%) 112
TARGETED DELIVERY 113
Market Leaders 113
TABLE 64 MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 113
Market Share 114
TABLE 65 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG
DELIVERY, 2012 (%) 114
FIGURE 38 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG
DELIVERY, 2012 (%) 114
POLYMERIC DRUG DELIVERY 115
Market Leaders 115
TABLE 66 MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 115
Market Share 116
TABLE 67 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG
DELIVERY, 2012 (%) 116
FIGURE 39 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG
DELIVERY, 2012 (%) 116

CHAPTER 8 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION 118

TABLE 68 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE
OF ADMINISTRATION, THROUGH 2018 ($ MILLIONS) 119
FIGURE 40 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE
OF ADMINISTRATION, 2011-2018 ($ MILLIONS) 119
MARKET BY TYPE 120
ORAL, TOPICAL AND INJECTABLE DRUG DELIVERIES 120
Market Overview 121
Market Revenue 122
TABLE 69 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY
BY TYPE, THROUGH 2018 ($ MILLIONS) 122
FIGURE 41 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY
BY TYPE, 2011-2018 ($ MILLIONS) 123
TRANSMUCOSAL DELIVERY SYSTEMS 123
Market Overview 124
Market Revenue 126
TABLE 70 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,
THROUGH 2018 ($ MILLIONS) 127
FIGURE 42 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,
2011-2018 ($ MILLIONS) 127
TRANSDERMAL DRUG DELIVERY SYSTEM 128
Market Overview 129
Market Revenue 129
TABLE 71 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,
THROUGH 2018 ($ MILLIONS) 129
FIGURE 43 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,
2011-2018 ($ MILLIONS) 129
MARKET BY REGION 130
MARKET OVERVIEW 130
MARKET REVENUE 131
Oral, Topical, Injectables 132
TABLE 72 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY
BY REGION, THROUGH 2018 ($ MILLIONS) 132
FIGURE 44 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY
BY REGION, 2011-2018 ($ MILLIONS) 132
Transmucosal Drug Delivery 133
TABLE 73 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 133
FIGURE 45 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 133
Transdermal Drug Delivery 134
TABLE 74 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 134
FIGURE 46 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,
2011-2018 ($ MILLIONS) 135
INDUSTRY STRUCTURE 135
ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY 135
Market Leaders 135
TABLE 75 MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG
DELIVERY, 2012 135
Market Share of Oral Drug Delivery 136
TABLE 76 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012
(%) 136
FIGURE 47 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012
(%) 137
Market Share of Injectable Drug Delivery 137
TABLE 77 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,
2012 (%) 137
FIGURE 48 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS,
2012 (%) 138
Market Share of Topical Drug Delivery 138
TABLE 78 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,
2012 (%) 138
FIGURE 49 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS,
2012 (%) 139
TRANSMUCOSAL DRUG DELIVERY 139
Market Leaders 139
TABLE 79 MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY 140
Market Share of Nasal Drug Delivery 141
TABLE 80 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL
DRUG DELIVERY, 2012 (%) 141
FIGURE 50 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL
DRUG DELIVERY, 2012 (%) 141
Market Share of Oral Mucosal/Buccal Drug Delivery 141
TABLE 81 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,
2012 (%) 142
FIGURE 51 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY,
2012 (%) 142
Market Share of Rectal Drug Delivery 142
TABLE 82 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,
2012 (%) 143
FIGURE 52 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY,
2012 (%) 143
Market Share of Ocular Drug Delivery 143
TABLE 83 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,
2012 (%) 144
FIGURE 53 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY,
2012 (%) 144
Market Share of Vaginal Drug Delivery 144
TABLE 84 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,
2012 (%) 145
FIGURE 54 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY,
2012 (%) 145
TRANSDERMAL DRUG DELIVERY 146
Market Leaders 146
TABLE 85 MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 146
Market Share 146
TABLE 86 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG
DELIVERY, 2012 (%) 146
FIGURE 55 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG
DELIVERY, 2012 (%) 147

CHAPTER 9 MARKET BY END USERS 149

TABLE 87 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY
APPLICATIONS, THROUGH 2018 ($ MILLIONS) 150
FIGURE 56 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY
APPLICATIONS, 2011-2018 ($ MILLIONS) 150
CARDIOVASCULAR DISEASES 151
MARKET REVENUE 152
TABLE 88 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,
THROUGH 2018 ($ MILLIONS) 152
FIGURE 57 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,
2011-2018 ($ MILLIONS) 152
MARKET SHARE 153
TABLE 89 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY
REGION, 2012 (%) 153
FIGURE 58 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY
REGION, 2012 (%) 153
ONCOLOGY 154
MARKET REVENUE 155
TABLE 90 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH
2018 ($ MILLIONS) 155
FIGURE 59 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS,
2011-2018 ($ MILLIONS) 155
MARKET SHARE 156
TABLE 91 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,
2012 (%) 156
FIGURE 60 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,
2012 (%) 156
GASTROINTESTINAL SYSTEMS 156
MARKET REVENUE 157
TABLE 92 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,
THROUGH 2018 ($ MILLIONS) 157
FIGURE 61 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,
2011-2018 ($ MILLIONS) 157
MARKET SHARE 158
TABLE 93 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY
SYSTEMS, 2012 (%) 158
FIGURE 62 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY
SYSTEMS, 2012 (%) 158
UROLOGY 159
MARKET REVENUE 160
TABLE 94 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH
2018 ($ MILLIONS) 160
FIGURE 63 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018
($ MILLIONS) 160
MARKET SHARE 160
TABLE 95 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,
2012 (%) 161
FIGURE 64 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,
2012 (%) 161
DIABETES 161
MARKET REVENUE 162
TABLE 96 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH
2018 ($ MILLIONS) 162
FIGURE 65 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES,
2011-2018 ($ MILLIONS) 162
MARKET SHARE 163
TABLE 97 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,
2012 (%) 163
FIGURE 66 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,
2012 (%) 163
CENTRAL NERVOUS SYSTEM 164
MARKET REVENUE 164
TABLE 98 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS, THROUGH 2018 ($ MILLIONS) 165
FIGURE 67 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS, 2011-2018 ($ MILLIONS) 165
MARKET SHARE 165
TABLE 99 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS BY REGION, 2012 (%) 166
FIGURE 68 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS BY REGION, 2012 (%) 166
RESPIRATORY DRUG DELIVERY SYSTEMS 166
MARKET REVENUE 167
TABLE 100 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,
THROUGH 2018 ($ MILLIONS) 167
FIGURE 69 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,
2011-2018 ($ MILLIONS) 167
MARKET SHARE 168
TABLE 101 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,
2012 (%) 168
FIGURE 70 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,
2012 (%) 168
INFLAMMATORY DISEASES AND ALLERGIES 168
MARKET REVENUE 169
TABLE 102 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY
DISEASES AND ALLERGIES, THROUGH 2018 ($ MILLIONS) 169
FIGURE 71 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY
DISEASES AND ALLERGIES, 2011-2018 ($ MILLIONS) 169
MARKET SHARE 170
TABLE 103 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY
DISEASES AND ALLERGIES BY REGION, 2012 (%) 170
FIGURE 72 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY
DISEASES AND ALLERGIES BY REGION, 2012 (%) 170
OPHTHALMOLOGY 171
MARKET REVENUE 172
TABLE 104 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,
THROUGH 2018 ($ MILLIONS) 172
FIGURE 73 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,
2011-2018 ($ MILLIONS) 172
MARKET SHARE 173
TABLE 105 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY
REGION, 2012 (%) 173
FIGURE 74 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY
REGION, 2012 (%) 173
VIRAL AND BACTERIAL DISEASES 174
MARKET REVENUE 174
TABLE 106 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES, THROUGH 2018 ($ MILLIONS) 174
FIGURE 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES, 2011-2018 ($ MILLIONS) 175
MARKET SHARE 175
TABLE 107 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES BY REGION, 2012 (%) 175
FIGURE 76 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES BY REGION, 2012 (%) 175
HORMONE REPLACEMENT THERAPY AND GYNECOLOGY 176
MARKET REVENUE 177
TABLE 108 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 ($ MILLIONS) 177
FIGURE 77 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 ($ MILLIONS) 177
MARKET SHARE 178
TABLE 109 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 178
FIGURE 78 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 178
OTHERS 179
MARKET REVENUE 180
TABLE 110 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,
THROUGH 2018 ($ MILLIONS) 180
FIGURE 79 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,
2911-2018 ($ MILLIONS) 180
MARKET SHARE 181
TABLE 111 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES,
2012 (%) 181
FIGURE 80 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES,
2012 (%) 181
MARKET SHARE OF APPLICATIONS 181
TABLE 112 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012
(%) 181
FIGURE 81 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012
(%) 182

CHAPTER 10 PATENT ANALYSIS 184

PATENTS BY YEAR 184
TABLE 113 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 184
FIGURE 82 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 184
PATENTS BY CATEGORY 185
TABLE 114 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 185
FIGURE 83 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 186
PATENTS BY TYPE 186
TABLE 115 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013 186
PATENTS BY COMPANY 187
TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013 187
PATENTS BY COUNTRY 189
TABLE 117 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013 189
PATENTS BY ASSIGNEE 190
TABLE 118 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 190
FIGURE 84 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 190

CHAPTER 11 CURRENT SITUATION 192

CHAPTER 12 COMPANY PROFILES 196

3M COMPANY 196
ABBOTT LABORATORIES 196
ACTAVIS INC. 197
AKELA PHARMA INC. 197
AKORN, INC. 198
ALCON INC. 198
ALEXION PHARMACEUTICALS, INC. 199
ALKERMES 199
ALLERGAN INC. 199
AMGEN INC. 200
A.P. PHARMA 201
APTALIS PHARMA INC. 201
ASTELLAS PHARMA INC. 202
ASTRAZENECA PLC 202
ATON PHARMA 203
BAUSCH and LOMB 203
BAXTER INTERNATIONAL INC. 203
BAYER HEALTHCARE PHARMACEUTICALS 204
BIOGEN IDEC 204
BIOSANTE PHARMACEUTICALS, INC. 205
BOEHRINGER INGELHEIM 205
BOSTON SCIENTIFIC 206
BRISTOL MYERS SQUIBB 206
CELGENE CORPORATION 207
CEPHALON, INC. 207
COLUMBIA LABORATORIES, INC. 208
EISAI CO., LTD 208
ELAN DRUG TECHNOLOGIES 209
ENZON PHARMACEUTICALS 209
GENENTECH INC. 210
GENEREX BIOTECHNOLOGY CORPORATION 210
GENZYME CORPORATION 211
GILEAD SCIENCES, INC. 212
GLAXOSMITHKLINE PLC 212
HISAMITSU PHARMACEUTICAL CO., INC. 213
IMCLONE SYSTEMS INC. 213
JANSSEN BIOTECH, INC. 214
JOHNSON and JOHNSON 214
KEMPHARM, INC. 215
K.V. PHARMACEUTICAL CO. 215
LAVIPHARM CORPORATION 216
MANNKIND CORPORATION 216
MERCK and CO. 217
MYLAN LABORATORIES INC. 217
NEKTAR THERAPEUTICS 218
NEUROGESX INC. 218
NEWGEN BIOPHARMA 219
NOVARTIS AG 219
NOVAVAX, INC. 220
NOVEN PHARMACEUTICALS, INC. 220
NYCOMED US INC. 221
OSI PHARMACEUTICALS, INC. 221
PAR PHARMACEUTICAL COMPANIES, INC. 222
PDL BIOPHARMA, INC. 222
PFIZER INC. 223
QLT INC. 223
ROCHE HOLDING AG 224
SANOFI SA 224
TEVA PHARMACEUTICAL INDUSTRIES LTD. 225
THERAJECT, INC. 226
UMEWORLD LTD. 226
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 227
XEL PHARMACEUTICALS, INC. 227

CHAPTER 13 APPENDIX I 229



LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY
REGION, THROUGH 2018 ($ MILLIONS) 7
TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10
TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG
DELIVERY 12
TABLE 3 CLASSIFICATION OF PRODRUGS 14
TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15
TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17
TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19
TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22
TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23
TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24
TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25
TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25
TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26
TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27
TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY 28
TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28
TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29
TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29
TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32
TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35
TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37
TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41
TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43
TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44
TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018
($ MILLIONS) 49
TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 50
TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 53
TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,
FOR 2012 (%) 54
TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 55
TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 56
TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($
MILLIONS) 58
TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 59
TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 62
TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%) 63
TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 65
TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 66
TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 67
TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,
2012 ($ MILLIONS) 68
TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 70
TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 71
TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,
THROUGH 2018 ($ MILLIONS) 77
TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,
2012 (%) 79
TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY
TECHNOLOGY, THROUGH 2018 ($ MILLIONS) 81
TABLE 43 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY
TYPE, THROUGH 2018 ($ MILLIONS) 85
TABLE 44 GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 ($ MILLIONS) 86
TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 87
TABLE 45 GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 ($ MILLIONS) 89
TABLE 46 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH
2018 ($ MILLIONS) 92
TABLE 47 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH
2018 ($ MILLIONS) 94
TABLE 48 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY
REGION, THROUGH 2018 ($ MILLIONS) 97
TABLE 49 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY
BY REGION, THROUGH 2018 ($ MILLIONS) 99
TABLE 50 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY
REGION, THROUGH 2018 ($ MILLIONS) 100
TABLE 51 GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 ($
MILLIONS) 100
TABLE 52 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($
MILLIONS) 102
TABLE 53 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 103
TABLE 54 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 104
TABLE 55 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY
REGION, THROUGH 2018 ($ MILLIONS) 105
TABLE 56 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 106
TABLE 57 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, THROUGH
2018 ($ MILLIONS) 107
TABLE 58 MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012 108
TABLE 59 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY,
2012 (%) 109
TABLE 60 MAJOR MANUFACTURERS OF PRODRUGS, 2012 110
TABLE 61 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%) 111
TABLE 62 MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012 112
TABLE 63 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012
(%) 112
TABLE 64 MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 113
TABLE 65 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY,
2012 (%) 114
TABLE 66 MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 115
TABLE 67 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY,
2012 (%) 116
TABLE 68 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF
ADMINISTRATION, THROUGH 2018 ($ MILLIONS) 119
TABLE 69 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY
BY TYPE, THROUGH 2018 ($ MILLIONS) 122
TABLE 70 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE,
THROUGH 2018 ($ MILLIONS) 127
TABLE 71 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS,
THROUGH 2018 ($ MILLIONS) 129
TABLE 72 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY
BY REGION, THROUGH 2018 ($ MILLIONS) 132
TABLE 73 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLIONS) 133
TABLE 74 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,
THROUGH 2018 ($ MILLION

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Pulmonary Drug Delivery Systems: Technologies and Global Markets

Pulmonary Drug Delivery Systems: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Receive a detailed analysis of the present and future global market for pulmonary drug delivery technologies. - Receive information on pulmonary drug delivery technologies currently ...

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

nebulizer is a medical device used for the treatment of respiratory disorders (asthma, COPD and cystic fibrosis) that converts liquid medication into mist or aerosol. Thus, the medicine can easily reach ...

Cytotoxic Drug Delivery

May 2014 $ 2 850

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.